Natural Alternatives International, Inc. Announces Fiscal 2027 Q1 Results
Key Highlights
- ➤Q1 net loss $2.5 million versus $0.3 million prior-year loss
- ➤Q1 net sales $28.1 million, down 25.5% year over year
- ➤Private-label sales fell 29.1% to $25.6 million
- ➤CarnoSyn revenue rose 54.0% to $2.6 million
- ➤NAI began reviewing strategic alternatives, including a potential sale
Expert Statements
Mark A. Le Doux, Chairman and Chief Executive Officer of Natural Alternatives International, Inc.
“While the results of this past quarter have been very disappointing, the recent reticence to meet forecast commitments by several customers, which significantly contributed to the quarter's poor sales performance, has begun to subside.”
Mark A. Le Doux, Chairman and Chief Executive Officer of Natural Alternatives International, Inc.
“Recent meetings with current and prospective clients have encouraged us to expand our research and formulation efforts to include combinations of CarnoSyn® with various popular peptides, showing promise in supporting human health.”
Mark A. Le Doux, Chairman and Chief Executive Officer of Natural Alternatives International, Inc.
“We also are actively reviewing our options to improve our manufacturing architecture, overhead absorption, and liquidity.”
Mark A. Le Doux, Chairman and Chief Executive Officer of Natural Alternatives International, Inc.
“We remain committed to right sizing the U.S. facilities to meet the needs of our current and prospective clients, as we also continue to promote the wide adoption of our IP estate in new applications.”
CARLSBAD, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, announced today a net loss of $2.5 million, or ($0.41) per diluted share, on net sales of $28.1 million for the first quarter of fiscal year 2027 compared to a net loss of $0.3 million, or ($0.05) per diluted share, in the first quarter of the prior fiscal year.
Net sales during the three months ended September 30, 2026, decreased $9.6 million, or 25.5%, to $28.1 million compared to $37.7 million recorded in the comparable prior year period. During the same period, private-label contract manufacturing sales decreased 29.1% to $25.6 million. Our Private-label contract manufacturing sales decreased primarily due to decreased orders from several of our larger customers associated with excess inventory positions and delayed product launches, partially offset by orders from new customer product launches.
Get started
Create a free account to read the full story.